Abstract
Diarrhoea and weight loss are frequently reported adverse events in rheumatoid arthritis (RA) patients receiving the disease-modifying antirheumatic drug (DMARD) leflunomide. According to the available literature these side effects occur mostly during the first 6 months of treatment, are rather mild and rarely lead to treatment withdrawal. In this report, we describe the clinical, endoscopic and histologic findings in two RA patients with severe diarrhoea and important weight loss more than 12 months after starting treatment with leflunomide. In both cases the symptoms were caused by colitis, but one had ulcerative and the other microscopic colitis. Despite treatment with budesonide the complaints only improved after withdrawal of leflunomide, making a causal relationship between this drug and the pathogenesis of colitis probable. The heterogeneous histopathological findings in these two patients, however, do not allow us to draw any definitive conclusions about the mechanism by which leflunomide causes diarrhoea and weight loss in RA patients. We conclude that persistent diarrhoea or weight loss in patients taking leflunomide can be more serious than what is previously reported in the literature. In such cases leflunomide treatment should be stopped and an endoscopic examination of the colon is recommended. Given the long half-life of this drug a washout procedure with cholestyramine should be considered whenever the problem is severe or persistent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Strand V, Cohen S, Schiff M et al, Leflunomide Rheumatoid Arthritis Investigators Group (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 159:2542–2550
Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multi-centre trial. Lancet 353:259–266
Emery P, Breedveld FC, Lemmel EM et al, Multinational Leflunomide Study Group (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655–665
Kremer JM, Genovese MC, Cannon GW, Caldwell RJ, Cush JJ, Furst DE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 137:716–733
Larsen A, Kvien TK, Schattenkirchner, Rau R, Scott DL et al, European Leflunomide Study Group (2001) Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 30:135–142
Mladenovic V, Domljan Z, Rozman B et al (1995) Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomised, placebo-controlled, phase II study. Arthritis Rheum 38:1595–1603
Coblyn JS, Shadick N, Helfgott S (2001) Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis Rheum 44:1048–1051
Kalden JR, Schattenkirchner M, Sörensen H et al (2003) The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up study. Arthritis Rheum 48:1513–1520
Maes B, Dalle I, Geboes K et al (2003) Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 75:665–672
Hammer B (1994) Current developments in the diagnosis and therapy of Crohn disease and ulcerative colitis. Schweiz Med Wochenschr 124:452–460
Davies NM, Can PD (1995) Toxicity of NSAIDs in the large intestine. Dis Colon Rectum 38:1311–1321
Wilcox GM, Mattia A (2002) Collagenous colitis associated with lansoprazole. J Clin Gastroenterol 34:164–166
Fernandez-Banares F, Salas A, Esteve M et al (2003) Collagenous and lymphocytic colitis. Evaluation of clinical and histological features, response to treatment, and long-term follow-up. Am J Gastroenterol 98:340–347
Püspök A, Kiener HP et al (2000) Clinical, endoscopic and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis Colon Rectum 43:685–691
Acknowledgements
The authors wish to thank Dr. G. Jacomen, A.Z. St-Maarten, campus Duffel Rooienberg 25 2570 Duffel and Dr. L. Cappelle, CAZ MIDDEN Limburg vzw campus Salvator Salvatorstraat 20 3500 Hasselt for their cooperation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verschueren, P., Vandooren, A. & Westhovens, R. Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. Clin Rheumatol 24, 87–90 (2005). https://doi.org/10.1007/s10067-004-1033-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-1033-1